180 Life Sciences (ATNF) said Thursday that the US Patent and Trademark Office has issued a notice of allowance for a patent application covering a new method to prevent post-operative cognitive dysfunction, or POCD.
The patent centers on preventing or reducing POCD by using an anti-human tumor necrosis factor alpha monoclonal antibody before and during surgery.
POCD is a complication affecting elderly surgical patients that leads to delirium, memory loss, and other cognitive impairments, the company said.
180 Life Sciences said a patent, if issued, would boost its biotechnology portfolio while it shifts focus toward online casino and entertainment ventures through its gaming platform.
Shares of 180 Life Sciences were up 11% in recent Thursday trading.
Price: 0.99, Change: +0.10, Percent Change: +11.01
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。